Dalvance and Infusion site extravasation - a phase IV clinical study of FDA data

Summary:

Infusion site extravasation is reported as a side effect among people who take Dalvance (dalbavancin hydrochloride), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Flagyl, and have Cellulitis.

The phase IV clinical study analyzes which people have Infusion site extravasation when taking Dalvance. It is created by eHealthMe based on reports of 601 people who have side effects when taking Dalvance from the FDA, and is updated regularly.

What is Dalvance?

Dalvance has active ingredients of dalbavancin hydrochloride. eHealthMe is studying from 602 Dalvance users. Check the latest studies of Dalvance.

What is Infusion site extravasation?

Infusion site extravasation (flow of (blood or lymph) from infusion site) is found to be associated with 646 drugs and 590 conditions by eHealthMe. Check the latest studies of Infusion site extravasation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

601 people reported to have side effects when taking Dalvance.
Among them, 19 people (3.16%) have Infusion site extravasation.

Could Dalvance cause Infusion site extravasation?

Among these 19 people:

How long have people been on Dalvance when they have Infusion site extravasation? *

What is the gender of people who have Infusion site extravasation when taking Dalvance? *

female: 27.27 %
male: 72.73 %

What is the age of people who have Infusion site extravasation when taking Dalvance? *

What are other drugs people take besides Dalvance? *

What are other side effects people have besides Infusion site extravasation? *

Swelling: 2 people, 10.53%
Infusion Site Pain: 2 people, 10.53%
Rashes (redness): 1 person, 5.26%
Itching: 1 person, 5.26%
Infusion Site Swelling: 1 person, 5.26%
Infusion Site Rash: 1 person, 5.26%
Infusion Site Paraesthesia (abnormal skin sensations at infusion site): 1 person, 5.26%
Infusion Site Oedema (swelling from excessive accumulation of watery fluid from infusion site): 1 person, 5.26%
Infusion Site Haematoma (localized swelling filled with blood at infusion site): 1 person, 5.26%
Infusion Site Erythema (reddening of the skin at infusion site): 1 person, 5.26%

What are the existing conditions these people have? *

Soft Tissue Infection: 2 people, 10.53%
Skin Infection: 2 people, 10.53%
Skin Bacterial Infection: 2 people, 10.53%
Osteomyelitis (infection of bone): 2 people, 10.53%
Localised Infection (infection at the single location): 2 people, 10.53%
Cellulitis (infection under the skin): 2 people, 10.53%
Wound: 1 person, 5.26%
Staphylococcal Infection (an infection with staphylococcus bacteria): 1 person, 5.26%
Diabetes: 1 person, 5.26%
Bursitis (inflammation of a bursa, typically one in the knee, elbow, or shoulder): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Dalvance and have Infusion site extravasation?

- Check whether Infusion site extravasation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dalvance:

Dalvance (602 reports)

Browse all side effects of Dalvance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infusion site extravasation:

Infusion site extravasation (646 drugs)

Browse all the conditions that are associated with Infusion site extravasation:

Infusion site extravasation (590 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dalbavancin hydrochloride (the active ingredients of Dalvance) and Dalvance (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.